Change of the 5α/5β ratio of urinary steroid metabolites in benign prostatic hyperplasia patients treated with dutasteride.

[1]  M. Hartmann,et al.  The urinary steroidome of treated children with classic 21-hydroxylase deficiency , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  T. Puzyn,et al.  Metabolomic Biomarkers in Urine of Cushing’s Syndrome Patients , 2017, International journal of molecular sciences.

[3]  Jayoung Kim,et al.  Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases , 2016, Endocrine-related cancer.

[4]  M. Carini,et al.  Metabolic syndrome and benign prostatic enlargement: a systematic review and meta‐analysis , 2015, BJU international.

[5]  W. Kuohung,et al.  5-Alpha reductase deficiency: a 40-year retrospective review , 2014, Current opinion in endocrinology, diabetes, and obesity.

[6]  Yi Zhi,et al.  Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients. , 2014, Urology.

[7]  P. Xie,et al.  A novel urinary metabolite signature for diagnosing major depressive disorder. , 2013, Journal of proteome research.

[8]  B. Keevil,et al.  Novel liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for measuring steroids. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[9]  Alexander Bachmann,et al.  EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. , 2013, European urology.

[10]  M. Murata,et al.  Measurement of reference intervals for urinary free adrenal steroid levels in Japanese newborn infants by using stable isotope dilution gas chromatography/mass spectrometry. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[11]  C. Roehrborn,et al.  Evaluation and treatment of lower urinary tract symptoms in older men. , 2009, The Journal of urology.

[12]  Michael Biehl,et al.  Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors , 2011, The Journal of clinical endocrinology and metabolism.

[13]  N. Masumori,et al.  Internal prostatic architecture on transrectal ultrasonography predicts future prostatic growth: Natural history of prostatic hyperplasia in a 15‐year longitudinal community‐based study , 2011, The Prostate.

[14]  John T. Wei,et al.  Update on AUA guideline on the management of benign prostatic hyperplasia. , 2011, The Journal of urology.

[15]  T. Remer,et al.  Profiling oestrogens and testosterone in human urine by stable isotope dilution/benchtop gas chromatography–mass spectrometry , 2010, Steroids.

[16]  T. Tsukamoto,et al.  Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia , 2009, International journal of urology : official journal of the Japanese Urological Association.

[17]  Giorgia Antonelli,et al.  Cortisol assays and diagnostic laboratory procedures in human biological fluids. , 2009, Clinical biochemistry.

[18]  Sang Deuk Kim,et al.  Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. , 2009, Urology.

[19]  M. Thevis,et al.  Doping-Control Analysis of the 5α-Reductase Inhibitor Finasteride: Determination of Its Influence on Urinary Steroid Profiles and Detection of Its Major Urinary Metabolite , 2007, Therapeutic drug monitoring.

[20]  Takao Takahashi,et al.  Elevated urine pregnanetriolone definitively establishes the diagnosis of classical 21-hydroxylase deficiency in term and preterm neonates. , 2004, The Journal of clinical endocrinology and metabolism.

[21]  M. Gleave,et al.  Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer , 2004 .

[22]  G. Cunningham,et al.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. , 2004, The Journal of clinical endocrinology and metabolism.

[23]  Takao Takahashi,et al.  Reference values for urinary steroids in Japanese newborn infants: gas chromatography/mass spectrometry in selected ion monitoring. , 2003, Endocrine journal.

[24]  J. Honour,et al.  Urinary steroid profile analysis. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[25]  J. Imperato-McGinley,et al.  C19 and C21 5β/5α Metabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency* , 1990 .